ISPOR - PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANY

Full Text

PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANY

Abstract

Authors

J. Mathes A. Höer

Back to Volume 21, Supplemental S3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now